[go: up one dir, main page]

ATE107176T1 - System zur transdermalen albuterol applikation. - Google Patents

System zur transdermalen albuterol applikation.

Info

Publication number
ATE107176T1
ATE107176T1 AT90123100T AT90123100T ATE107176T1 AT E107176 T1 ATE107176 T1 AT E107176T1 AT 90123100 T AT90123100 T AT 90123100T AT 90123100 T AT90123100 T AT 90123100T AT E107176 T1 ATE107176 T1 AT E107176T1
Authority
AT
Austria
Prior art keywords
patch
application
albuterol
transdermal albuterol
transdermal
Prior art date
Application number
AT90123100T
Other languages
English (en)
Inventor
Bahram Farhadieh
Rajeeve Dattatrey Gokhale
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE107176T1 publication Critical patent/ATE107176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90123100T 1989-12-04 1990-12-03 System zur transdermalen albuterol applikation. ATE107176T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42576689A 1989-12-04 1989-12-04

Publications (1)

Publication Number Publication Date
ATE107176T1 true ATE107176T1 (de) 1994-07-15

Family

ID=23687946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90123100T ATE107176T1 (de) 1989-12-04 1990-12-03 System zur transdermalen albuterol applikation.

Country Status (11)

Country Link
US (2) US5164189A (de)
EP (1) EP0431519B1 (de)
JP (1) JPH07133230A (de)
KR (1) KR910011247A (de)
AT (1) ATE107176T1 (de)
CA (1) CA2031376A1 (de)
DE (1) DE69009946T2 (de)
DK (1) DK0431519T3 (de)
ES (1) ES2055280T3 (de)
IE (1) IE66203B1 (de)
PT (1) PT96059B (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679399A (en) 1987-07-17 1997-10-21 Bio Barrier, Inc. Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
US5549924A (en) * 1987-07-17 1996-08-27 Robin Renee Thill Shlenker Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
JPH01153633A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 経皮吸収製剤
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US20050152950A1 (en) * 1995-11-13 2005-07-14 Saffran Bruce N. Method and apparatus for macromolecular delivery using a coated membrane
US5708036A (en) * 1996-01-29 1998-01-13 Pesterfield, Jr.; E. Charles Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
CA2247953A1 (en) * 1996-01-29 1997-07-31 E. Charles Pesterfield Jr. Method of treating undesired uterine contractions using optically pure r- or rr-isomers of adrenergic beta-2 agonists
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9719076D0 (en) * 1997-09-09 1997-11-12 Movevirgo Limited A material for producing a medical dressing and a medical dressing produced using the material
CN100357143C (zh) * 1998-01-20 2007-12-26 易通公司 起步发动机扭矩限制
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
KR100369779B1 (ko) * 1999-07-12 2003-01-29 주식회사 엘지생명과학 교감신경 흥분성 기관지확장 약물의 경피흡수 투여용 조성물및 이를 포함하는 경피흡수 투여용 제형
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US20070218087A1 (en) * 2001-12-07 2007-09-20 Norbert Hoenzelaer Method of controlled release of vanillin for nasal and/or pulmonary uptake
DE10200578A1 (de) * 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1546184A4 (de) * 2002-07-16 2006-08-23 Univ South Florida Humanes immunosuppressives protein
EP2130541A3 (de) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Verfahren zur Behandlung oder Vorbeugung von Autoimmunerkrankungen mit 2,4-Pyrimidindiaminverbindungen
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
CA2506615A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
EP1590743A1 (de) * 2003-01-21 2005-11-02 Alza Corporation Rechnerisches modell für die transdermale medikamentenverabreichung
WO2004094457A2 (en) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Stable rgd peptidomimetic composition
WO2005013996A2 (en) 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
US8168600B2 (en) * 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
EP2007877B1 (de) 2006-02-28 2013-04-17 The Trustees of Columbia University in the City of New York Verfahren für kompakte aggregation von hautzellen
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
ATE497496T1 (de) 2006-10-19 2011-02-15 Rigel Pharmaceuticals Inc 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
CA2673137C (en) 2006-11-21 2015-02-10 Rigel Pharmaceuticals, Inc. Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
CA2835910C (en) * 2007-04-25 2016-06-28 Warner Chilcott Company, Llc Improved vitamin d content uniformity in pharmaceutical dosage forms
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
WO2009027850A2 (en) * 2007-06-06 2009-03-05 Multi-Tech Specialty Chemicals Co., Ltd. Process for the preparation of xanthophyll crystals
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
EP2278879B1 (de) * 2008-04-21 2016-06-15 PATH Drug Solutions Verbindungen, zusammensetzungen und verfahren umfassend oxadiazolderivate
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
RS54413B1 (sr) * 2008-08-22 2016-04-28 Sanofi [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
ES2624622T3 (es) 2008-12-30 2017-07-17 Rigel Pharmaceuticals, Inc. Inhibidores de pirimidindiamina cinasa
JP5802136B2 (ja) 2009-01-23 2015-10-28 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2451796B1 (de) 2009-07-08 2013-04-17 Dermira (Canada), Inc. Tofa-analoga zur behandlung von hauterkrankungen oder -störungen
US20110034415A1 (en) 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
SG181594A1 (en) 2009-12-23 2012-07-30 Sanofi Sa [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
MY155980A (en) 2009-12-23 2015-12-31 Sanofi Sa Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
CN103096889A (zh) 2010-04-20 2013-05-08 寰宇一家健康研究所 包含1,3,4-噁二唑衍生物的化合物、组合物和方法
WO2011133600A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
HUE026474T2 (en) 2010-04-24 2016-06-28 Viamet Pharmaceuticals Inc Metalloenzyme inhibitor compounds
US20120208855A1 (en) 2010-07-12 2012-08-16 Sanofi Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
BR112013001632B1 (pt) 2010-07-28 2021-05-25 Rigel Pharmaceuticals composto, composição farmacêutica, e, método de fabricar um composto
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
WO2012058529A2 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
PL2635299T3 (pl) 2010-11-02 2020-03-31 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
EA024197B1 (ru) 2010-11-13 2016-08-31 Иннокрин Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CN103328452A (zh) 2010-12-13 2013-09-25 威尔金制药有限公司 金属酶抑制剂化合物
CN103649028B (zh) 2011-02-25 2015-10-14 美国政府健康及人类服务部 抑制FtsZ蛋白的克利斯汀类似物
WO2012122313A2 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted nanocarrier systems for delivery of actives across biological membranes
PH12013502624A1 (en) 2011-06-19 2014-02-17 Viamet Pharmaceuticals Inc Metalloenzyme inhibitor compounds
EP3067350B1 (de) 2011-06-19 2018-06-13 Viamet Pharmaceuticals (NC), Inc. Metalloenzyminhibitorverbindungen
KR101964195B1 (ko) 2011-06-23 2019-04-01 비아멧 파마슈티컬즈(엔씨), 인코포레이티드 금속효소 억제제 화합물
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
JP2014531425A (ja) 2011-09-02 2014-11-27 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 肥満の代謝異常を治療するためのＣａＭＫＩＩ、ＩＰ３Ｒ、カルシニューリン、ｐ３８、およびＭＫ２／３阻害剤
KR102070345B1 (ko) 2011-12-11 2020-01-28 마이코비아 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
WO2013109998A1 (en) 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2828241B1 (de) 2012-03-23 2018-09-12 Mateon Therapeutics, Inc. Zusammensetzungen und verfahren zur hemmung von cathepsinen
SI2830662T1 (sl) 2012-03-29 2019-01-31 The Trustees Of Columbia University In The City Of New York Postopki zdravljenja motenj izgube las
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2872126B1 (de) * 2012-07-16 2017-12-06 Grünenthal GmbH Pharmazeutisches pflaster zur transdermalen verabreichung von tapentadol
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
AU2014209263B2 (en) 2013-01-25 2018-11-01 Rigel Pharmaceuticals, Inc. Compounds and methods for treating inflammatory bowel diseases
CA2907152A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2015134920A1 (en) 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
AU2015231238B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
MX381344B (es) 2015-03-19 2025-03-12 Mycovia Pharmaceuticals Inc Compuestos antifungicos y procesos para la fabricacion.
WO2017023941A1 (en) 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
WO2017049096A1 (en) 2015-09-18 2017-03-23 Viamet Pharmaceuticals, Inc. Antifungal compound process
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
WO2017117393A1 (en) 2015-12-30 2017-07-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2018005356A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
WO2018002888A1 (en) 2016-06-29 2018-01-04 Halo Life Science, Llc Methods of making low odor choline salts of an organic compound
ES2946001T3 (es) 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
WO2018089199A1 (en) 2016-10-26 2018-05-17 Rigel Pharmaceuticals, Inc. Oxazole derivatives for use as irak inhibitors and method for their preparation
EP3562487B1 (de) 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzym-inhibitor-verbindungen
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
EP3645525A1 (de) 2017-06-29 2020-05-06 Rigel Pharmaceuticals, Inc. Kinasehemmer und verfahren zu ihrer herstellung und verwendung
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
PL3788045T3 (pl) 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
CR20200581A (es) 2018-05-03 2021-05-11 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
EP3908319B1 (de) 2019-01-08 2023-10-18 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzym-inhibitor-verbindungen
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
EP4009974A1 (de) 2019-08-08 2022-06-15 Rigel Pharmaceuticals, Inc. Verbindungen und verfahren zur behandlung des zytokinfreisetzungssyndroms
BR112022001896A2 (pt) 2019-08-14 2022-06-21 Rigel Pharmaceuticals Inc Método para bloquear ou atenuar síndrome de liberação de citocinas
JOP20220050A1 (ar) 2019-08-30 2023-01-30 Rigel Pharmaceuticals Inc مركبات بيرازول، صياغات منها وطريقة لاستخدام المركبات و/ أو صياغات
PH12022550537A1 (en) 2019-09-06 2023-03-20 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same.
AU2020343681B2 (en) 2019-09-06 2024-01-18 Rigel Pharmaceuticals, Inc. Heterocyclic RIP1 kinase inhibitors
HRP20251589T1 (hr) 2019-11-07 2026-01-30 Rigel Pharmaceuticals, Inc. Heterociklični spojevi koji inhibiraju rip1
US12357623B2 (en) 2021-03-03 2025-07-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
IL315677A (en) 2022-03-23 2024-11-01 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US4136219A (en) * 1973-02-09 1979-01-23 Odam Norman E Method of applying polyurethane paint to vulcanized rubber
US3935329A (en) * 1973-05-09 1976-01-27 Sheller-Globe Corporation Method of manufacturing new paintable rubber products
US4562075A (en) * 1982-05-20 1985-12-31 Nelson Research & Development Co. Penetration enhancers for transdermal drug delivery of systemic agents
DE2751328A1 (de) * 1976-12-21 1978-06-29 Gen Electric Durch ultraschall verbindbare polyphenylenaether-zusammensetzungen
JPS55139449A (en) * 1979-04-18 1980-10-31 Mitsubishi Gas Chem Co Inc Resin composition
DE3010374A1 (de) * 1980-03-18 1981-10-08 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten
JPS5812304B2 (ja) * 1980-09-16 1983-03-07 旭化成株式会社 芳香族ポリエ−テル樹脂組成物
DE3102253A1 (de) * 1981-01-24 1982-09-02 Basf Ag, 6700 Ludwigshafen Thermoplastische formmasse
AU564528B2 (en) * 1981-02-26 1987-08-13 General Electric Company Polyphenylene ether compositions and process
US4513120A (en) * 1981-03-23 1985-04-23 General Electric Company Polyphenylene ether compositions
JPS57174344A (en) * 1981-04-21 1982-10-27 Mitsubishi Gas Chem Co Inc Impact-resistant polyphenylene ether resin composition
US4360618A (en) * 1981-11-19 1982-11-23 Monsanto Company Low acrylonitrile content styrene-acrylonitrile polymers blended with polyphenylene oxide
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
JPS59204650A (ja) * 1983-05-10 1984-11-20 Japan Synthetic Rubber Co Ltd 熱可塑性樹脂組成物
KR860001431B1 (ko) * 1983-07-01 1986-09-24 닛뽕 고오세이 고무 가부시기 가이샤 열가소성 수지 조성물
NL8303497A (nl) * 1983-10-12 1985-05-01 Gen Electric Voorwerp geheel of gedeeltelijk vervaardigd uit een polymeermengsel en voorzien van een polyurethaanlaklaag of een polyurethaanlijmlaag.
US4578423A (en) * 1983-12-12 1986-03-25 Monsanto Company Polyblends of polyphenylene oxide and styrene-acrylonitrile polymers having broad acrylonitrile compositional distribution
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
DE3347278A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
DE3347277A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
EP0150021A3 (de) * 1984-01-20 1987-07-15 General Electric Company Polyphenylenätherharzzusammensetzungen mit verbessertem Schmelzfliess- und Überzugsvermögen
US4605670A (en) * 1984-02-01 1986-08-12 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering metoclopramide
DE3409079A1 (de) * 1984-03-13 1985-09-19 Bayer Ag, 5090 Leverkusen Medizinische pflaster
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
DE3586707T2 (de) * 1984-10-05 1993-02-11 Hercon Lab System zur transdermalen applikation eines arzneimittels.
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4638043A (en) * 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
ATE77962T1 (de) * 1985-02-25 1992-07-15 Univ Rutgers Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
US4699777A (en) * 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
CA1288698C (en) * 1985-08-30 1991-09-10 Yie W. Chien Transdermal anti-anginal pharmaceutical dosage
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
JPH0747535B2 (ja) * 1985-11-26 1995-05-24 日東電工株式会社 消炎鎮痛用貼付剤
JPS6310716A (ja) * 1986-07-02 1988-01-18 Teijin Ltd β−刺激薬外用剤
ZA875317B (en) * 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
US4820525A (en) * 1987-09-17 1989-04-11 American Home Products Corporation (Del.) Transdermal drug delivery system
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems

Also Published As

Publication number Publication date
IE66203B1 (en) 1995-12-13
PT96059A (pt) 1991-09-30
PT96059B (pt) 1998-07-31
DE69009946D1 (de) 1994-07-21
EP0431519B1 (de) 1994-06-15
US5164189A (en) 1992-11-17
ES2055280T3 (es) 1994-08-16
KR910011247A (ko) 1991-08-07
JPH07133230A (ja) 1995-05-23
DE69009946T2 (de) 1994-11-03
IE904345A1 (en) 1991-06-05
US5290561A (en) 1994-03-01
CA2031376A1 (en) 1991-06-05
DK0431519T3 (da) 1994-07-04
EP0431519A1 (de) 1991-06-12

Similar Documents

Publication Publication Date Title
DE69009946D1 (de) System zur transdermalen Albuterol Applikation.
DE3685895D1 (de) Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
DE69414502D1 (de) Medizinische Vorrichtung zur Verabreichung von Aktivsubstanzen oder Arzneistoffen in sehr niedriger Dosis, insbesondere von homöopatischen Arzneistoffen
WO1987003490A3 (en) Transdermal delivery system
DE3872109D1 (de) Vorrichtung zur transkutanen wirkstoffabgabe mit doppeltem durchgangsverstaerker.
FI905718A0 (fi) Transdermalt medel.
DE69637061D1 (de) Neue formulierungen zur transdermalen verabreichung von pergolid
EP0887075A3 (de) Klebstoffmasse zur transdermalen Verabreichung von stark weichmachenden Wirkstoffen
TW252919B (de)
ATE204160T1 (de) Formulierung zur inhalativen applikation
ATE230980T1 (de) Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden
ATE259226T1 (de) Zusammmensetzungen und verfahren zur verminderung der atmungsdepressionen und begleitender nebenmwirkungen von mu-opioid-verbindungen
DK239288A (da) Transdermal absorptionsdosisenhed til narkotiske analgetika og antagonister
DE3751917D1 (de) Iontotherapeutische vorrichtung mit dosiereinheit
EP0705097A1 (de) Einarbeitung eines poly-n-vinylamids in ein transdermales system
DE69430132D1 (de) Pernasale zusammensetzung und diese enthaltende pernasale zubereitung
DE3587048D1 (de) Pharmazeutische praeparate.
DE69730988D1 (de) Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat
BR9304431A (pt) Medicamento processo para sua preparaçao e aplicaçao de uma mistura
FR2706255B1 (fr) Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
AU625402B2 (en) Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
DE68929117D1 (de) Chemische Verbindungen und pharmazeutische Zusammensetzungen zur Freisetzung von Arzneimitteln
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
DE69918124D1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam
RU93004536A (ru) Лекарство для профилактики и терапии неврологических и психиатрических нарушений, возникающих при употреблении алкоголя

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee